{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:54:57Z","timestamp":1781646897155,"version":"3.54.5"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":49,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Patients presenting for outpatient surgery may have several comorbidities, including obesity and obstructive sleep apnea. The objective was to measure the efficacy of sugammadex (versus neostigmine) in reducing post-anesthesia care unit length of stay among obese patients with obstructive sleep apnea undergoing outpatient surgery. Furthermore, we aimed to assess differences in post- and pre-operative pulmonary function test and arterial blood gas metrics. We hypothesized that sugammadex would improve recovery times. This was a single institution randomized controlled double-masked clinical trial assessing the efficacy of sugammadex versus neostigmine in reducing length of stay among obese patients with obstructive sleep apnea undergoing outpatient surgery. Secondary outcomes included changes in pulmonary function test and arterial blood gas measurements postoperatively. Mann Whitney U test was the primary statistic used to compare primary and secondary outcomes. There were 90 subjects enrolled, divided equally into the neostigmine and sugammadex cohorts. The median [quartile] length of stay was 125\u00a0min [73, 186] versus 123\u00a0min [94, 169] in the neostigmine and sugammadex cohorts, respectively (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.79). There were no statistically significant differences in proportional changes of pulmonary function tests (all\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&gt;\u20090.05) nor arterial blood gas measurements (all\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&gt;\u20090.05). This suggests that among patients with obesity and OSA undergoing low-to-moderate risk surgery in the outpatient setting, routine use of one reversal agent over the other would not affect overall PACU efficiency in an ambulatory surgery center. Trial registration: Clinicaltrials.gov NCT04570150, Principal investigator: Jerry Ingrande, Date of registration: 29\/09\/2020).\n                  <\/jats:p>","DOI":"10.1038\/s41598-026-47043-2","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T09:48:35Z","timestamp":1774950515000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neostigmine versus sugammadex on outpatient recovery among obese patients with obstructive sleep apnea: A randomized controlled trial"],"prefix":"10.1038","volume":"16","author":[{"given":"Rodney A.","family":"Gabriel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian P.","family":"Curran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Engy T.","family":"Said","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paige S.","family":"Tsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dale N.","family":"Bongbong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam S.","family":"Deconde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol H.","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"Ingrande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"key":"47043_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinane.2020.110109","volume":"68","author":"RA Gabriel","year":"2021","unstructured":"Gabriel, R. A., Waterman, R. S., Burton, B. N., Scandurro, S. & Urman, R. D. Patient health status and case complexity of outpatient surgeries at various facility types in the United States: An analysis using the National Anesthesia Clinical Outcomes Registry. J. Clin. Anesth. 68, 110109 (2021).","journal-title":"J. Clin. Anesth."},{"issue":"6","key":"47043_CR2","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1213\/ANE.0000000000005282","volume":"133","author":"JJ Reeves","year":"2021","unstructured":"Reeves, J. J., Waterman, R. S., Spurr, K. R. & Gabriel, R. A. Efficiency metrics at an academic freestanding ambulatory surgery center: Analysis of the impact on scheduled end-times. Anesth. Analg. 133(6), 1406\u201314 (2021).","journal-title":"Anesth. Analg."},{"issue":"6","key":"47043_CR3","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1213\/ANE.0000000000005605","volume":"133","author":"N Rajan","year":"2021","unstructured":"Rajan, N., Rosero, E. B. & Joshi, G. P. Patient Selection for Adult Ambulatory Surgery: A Narrative Review. Anesth. Analg. 133 (6), 1415\u20131430 (2021).","journal-title":"Anesth. Analg"},{"issue":"1","key":"47043_CR4","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1097\/ALN.0000000000001409","volume":"126","author":"SJ Brull","year":"2017","unstructured":"Brull, S. J. & Kopman, A. F. Current status of neuromuscular reversal and monitoring: Challenges and opportunities. Anesthesiology 126(1), 173\u201390 (2017).","journal-title":"Anesthesiology"},{"issue":"6","key":"47043_CR5","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1213\/ANE.0000000000005657","volume":"133","author":"LD Bash","year":"2021","unstructured":"Bash, L. D., Black, W., Turzhitsky, V. & Urman, R. D. Neuromuscular blockade and reversal practice variability in the outpatient setting: Insights from US utilization patterns. Anesth. Analg. 133(6), 1437\u201350 (2021).","journal-title":"Anesth. Analg."},{"key":"47043_CR6","doi-asserted-by":"publisher","DOI":"10.1177\/01455613221132391","author":"PR Ellison","year":"2023","unstructured":"Ellison, P. R. et al. Optimizing Reversal of Muscle Relaxation with Sugammadex to Accelerate Discharge Readiness in Operative Laryngoscopy: A Randomized Clinical Trial. Ear Nose Throat J https:\/\/doi.org\/10.1177\/01455613221132391 (2023).","journal-title":"Ear Nose Throat J"},{"key":"47043_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.1072711","volume":"9","author":"J Fiorda Diaz","year":"2022","unstructured":"Fiorda Diaz, J. et al. Sugammadex versus neostigmine for neuromuscular blockade reversal in outpatient surgeries: A randomized controlled trial to evaluate efficacy and associated healthcare cost in an academic center. Front. Med. 9, 1072711 (2022).","journal-title":"Front. Med."},{"issue":"3","key":"47043_CR8","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1213\/ANE.0000000000006219","volume":"136","author":"C Huang","year":"2023","unstructured":"Huang, C. et al. Sugammadex Versus Neostigmine for Recovery of Respiratory Muscle Strength Measured by Ultrasonography in the Postextubation Period: A Randomized Controlled Trial. Anesth. Analg. 136 (3), 559\u2013568 (2023).","journal-title":"Anesth. Analg"},{"issue":"4","key":"47043_CR9","first-page":"311","volume":"9","author":"O Ekinci","year":"2022","unstructured":"Ekinci, O., Gulmez, D. D., Subasi, F. D., Ozgultekin, A. & Demiroluk, O. Neostigmine versus sugammadex on post-operative recovery following bariatric surgery. North Clin. Istanb. 9(4), 311\u20136 (2022).","journal-title":"North Clin. Istanb."},{"key":"47043_CR10","volume":"2022","author":"B Olesnicky","year":"2022","unstructured":"Olesnicky, B., Doane, M., Farrell, C., Knoblanche, G. & Delaney, A. Prevention of postoperative events following reversal with sugammadex or neostigmine (the P-PERSoN trial): Pilot data following early termination of a prospective, blinded, randomised trial. Anesthesiol. Res. Pract. 2022, 4659795 (2022).","journal-title":"Anesthesiol. Res. Pract."},{"issue":"9","key":"47043_CR11","doi-asserted-by":"publisher","first-page":"3626","DOI":"10.1053\/j.jvca.2022.03.033","volume":"36","author":"Y Yu","year":"2022","unstructured":"Yu, Y. et al. Sugammadex versus neostigmine for neuromuscular block reversal and postoperative pulmonary complications in patients undergoing resection of lung cancer. J. Cardiothorac. Vasc. Anesth. 36(9), 3626\u201333 (2022).","journal-title":"J. Cardiothorac. Vasc. Anesth."},{"issue":"6","key":"47043_CR12","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1213\/ANE.0000000000005533","volume":"132","author":"E Farag","year":"2021","unstructured":"Farag, E. et al. Sugammadex versus neostigmine for reversal of rocuronium neuromuscular block in patients having catheter-based neurointerventional procedures: A randomized trial. Anesth. Analg. 132(6), 1666\u201376 (2021).","journal-title":"Anesth. Analg."},{"issue":"8","key":"47043_CR13","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1007\/s12630-020-01695-4","volume":"67","author":"RE Abola","year":"2020","unstructured":"Abola, R. E. et al. A randomized-controlled trial of sugammadex versus neostigmine: Impact on early postoperative strength. Can. J. Anaesth. 67(8), 959\u201369 (2020).","journal-title":"Can. J. Anaesth."},{"issue":"11","key":"47043_CR14","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1007\/s12630-019-01419-3","volume":"66","author":"E Alday","year":"2019","unstructured":"Alday, E., Mu\u00f1oz, M., Planas, A., Mata, E. & Alvarez, C. Effects of neuromuscular block reversal with sugammadex versus neostigmine on postoperative respiratory outcomes after major abdominal surgery: A randomized-controlled trial. Can. J. Anaesth. 66(11), 1328\u20131337 (2019).","journal-title":"Can. J. Anaesth."},{"key":"47043_CR15","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jclinane.2017.06.006","volume":"41","author":"WJ Herring","year":"2017","unstructured":"Herring, W. J. et al. Sugammadex efficacy for reversal of rocuronium- and vecuronium-induced neuromuscular blockade: A pooled analysis of 26 studies. J. Clin. Anesth. 41, 84\u201391 (2017).","journal-title":"J. Clin. Anesth."},{"issue":"3","key":"47043_CR16","doi-asserted-by":"publisher","first-page":"309","DOI":"10.4103\/sja.SJA_113_17","volume":"11","author":"A Alsaeed","year":"2017","unstructured":"Alsaeed, A. et al. Sugammadex versus two doses of neostigmine for reversal of rocuronium in gastric sleeve surgery. Saudi J. Anaesth. 11(3), 309\u201311 (2017).","journal-title":"Saudi J. Anaesth."},{"issue":"6","key":"47043_CR17","doi-asserted-by":"publisher","first-page":"387","DOI":"10.5152\/TJAR.2015.35682","volume":"43","author":"DY \u00dcnal","year":"2015","unstructured":"\u00dcnal, D. Y. et al. Comparison of sugammadex versus neostigmine costs and respiratory complications in patients with obstructive sleep apnoea. Turk. J. Anaesthesiol. Reanim. 43(6), 387\u201395 (2015).","journal-title":"Turk. J. Anaesthesiol. Reanim."},{"issue":"1","key":"47043_CR18","doi-asserted-by":"publisher","first-page":"111","DOI":"10.4103\/aer.aer_79_21","volume":"15","author":"Y Subramani","year":"2021","unstructured":"Subramani, Y. et al. Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in morbidly obese adult patients: A systematic review and meta-analysis. Anesth. Essays Res. 15(1), 111\u20138 (2021).","journal-title":"Anesth. Essays Res."},{"key":"47043_CR19","doi-asserted-by":"crossref","unstructured":"Samad, M. et al. Perioperative efficiency of sugammadex following minimally invasive gastric sleeve surgery: A superiority trial. J. Perioper Pract. :17504589241267859. (2024).","DOI":"10.1177\/17504589241267859"},{"issue":"2","key":"47043_CR20","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1111\/cts.12941","volume":"14","author":"K Mostoller","year":"2021","unstructured":"Mostoller, K., Wrishko, R., Maganti, L., Herring, W. J. & van Zutphen- Geffen, M. Pharmacokinetics of sugammadex dosed by actual and ideal body weight in patients with morbid obesity undergoing surgery. Clin. Transl. Sci. 14(2), 737\u201344 (2021).","journal-title":"Clin. Transl. Sci."},{"issue":"1","key":"47043_CR21","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12871-021-01278-w","volume":"21","author":"JC Horrow","year":"2021","unstructured":"Horrow, J. C. et al. Actual versus ideal body weight dosing of sugammadex in morbidly obese patients offers faster reversal of rocuronium- or vecuronium-induced deep or moderate neuromuscular block: A randomized clinical trial. BMC Anesthesiol. 21(1), 62 (2021).","journal-title":"BMC Anesthesiol."},{"issue":"10","key":"47043_CR22","volume":"16","author":"PP Deshmukh","year":"2024","unstructured":"Deshmukh, P. P. & Chakole, V. Post-anesthesia recovery: A comprehensive review of sampe, modified aldrete, and white scoring systems. Cureus 16(10), e70935 (2024).","journal-title":"Cureus"},{"key":"47043_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcorm.2021.100165","author":"F Dexter","year":"2021","unstructured":"Dexter, F. & Epstein, R. H. Implications of the log-normal distribution for updating estimates of the time remaining until ready for phase I post-anesthesia care unit discharge. Perioperative Care and Operating Room Management https:\/\/doi.org\/10.1016\/j.pcorm.2021.100165 (2021).","journal-title":"Perioperative Care and Operating Room Management"},{"issue":"4","key":"47043_CR24","first-page":"211","volume":"34","author":"J Raft","year":"2015","unstructured":"Raft, J., Millet, F. & Meistelman, C. Example of cost calculations for an operating room and a post-anaesthesia care unit. Anaesth. Crit. Care Pain Med. 34 (4), 211\u2013215 (2015).","journal-title":"Anaesth. Crit. Care Pain Med."},{"issue":"2","key":"47043_CR25","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.bja.2023.04.037","volume":"131","author":"K Bartels","year":"2023","unstructured":"Bartels, K., Fernandez-Bustamante, A. & Vidal Melo, M. F. Reversal of neuromuscular block: What are the costs?. Br. J. Anaesth. 131(2), 202\u20134 (2023).","journal-title":"Br. J. Anaesth."},{"key":"47043_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/jpm15030087","author":"HT Hsu","year":"2025","unstructured":"Hsu, H. T. et al. Impact of Enhanced Recovery After Surgery with Neuromuscular Monitoring and Sugammadex on Healthcare Costs and Effectiveness of Recovery in Patients Following Anterior Cervical Spine Discectomy. Journal of Personalized Medicine https:\/\/doi.org\/10.3390\/jpm15030087 (2025).","journal-title":"Journal of Personalized Medicine"},{"issue":"8","key":"47043_CR27","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1097\/PTS.0000000000001036","volume":"18","author":"S Alonso","year":"2022","unstructured":"Alonso, S., Du, A. L., Waterman, R. S. & Gabriel, R. A. Body mass index is not an independent factor associated with recovery room length of stay for patients undergoing outpatient surgery. J. Patient Saf. 18(8), 742\u2013746 (2022).","journal-title":"J. Patient Saf."},{"issue":"4","key":"47043_CR28","doi-asserted-by":"publisher","first-page":"292","DOI":"10.31486\/toj.22.0064","volume":"22","author":"C Lee","year":"2022","unstructured":"Lee, C. et al. Perioperative efficiency of sugammadex following laparoscopic cholecystectomy in clinical practice. Ochsner Journal 22(4), 292\u20138 (2022).","journal-title":"Ochsner Journal"},{"issue":"6","key":"47043_CR29","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1097\/ALN.0000000000003256","volume":"132","author":"S Kheterpal","year":"2020","unstructured":"Kheterpal, S. et al. Sugammadex versus Neostigmine for Reversal of Neuromuscular Blockade and Postoperative Pulmonary Complications (STRONGER): A Multicenter Matched Cohort Analysis. Anesthesiology 132 (6), 1371\u20131381 (2020).","journal-title":"Anesthesiology"},{"key":"47043_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinane.2020.110027","volume":"67","author":"WE Hurford","year":"2020","unstructured":"Hurford, W. E., Welge, J. A. & Eckman, M. H. Sugammadex versus neostigmine for routine reversal of rocuronium block in adult patients: A cost analysis. J. Clin. Anesth. 67, 110027 (2020).","journal-title":"J. Clin. Anesth."},{"issue":"2","key":"47043_CR31","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.bja.2022.10.015","volume":"130","author":"LJ Wachtendorf","year":"2023","unstructured":"Wachtendorf, L. J. et al. Comparison of the effects of sugammadex versus neostigmine for reversal of neuromuscular block on hospital costs of care. Br. J. Anaesth. 130(2), 133\u201341 (2023).","journal-title":"Br. J. Anaesth."},{"issue":"6","key":"47043_CR32","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1097\/ALN.0000000000003735","volume":"134","author":"G Li","year":"2021","unstructured":"Li, G. et al. Postoperative pulmonary complications\u2019 association with sugammadex versus neostigmine: A retrospective registry analysis. Anesthesiology 134(6), 862\u201373 (2021).","journal-title":"Anesthesiology"},{"key":"47043_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinane.2020.109895","volume":"65","author":"M Carron","year":"2020","unstructured":"Carron, M., Linassi, F. & De Cassai, A. Role of sugammadex in accelerating postoperative discharge: An updated meta-analysis. J. Clin. Anesth. 65, 109895 (2020).","journal-title":"J. Clin. Anesth."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-47043-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-47043-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-47043-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:14:04Z","timestamp":1781644444000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-47043-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["47043"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-47043-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"assertion":[{"value":"19 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Supported in part by a research grant from Investigator-Initiated Studies Program of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. The opinions expressed in this paper are those of the authors and do not necessarily represent those of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. RG and ES\u2019s institution has received funding and\/or product for research purposes from Epimed, Infutronix, SPR Therapeutics, Merck & Co, Inc, and Precision Genetics. Dr Gabriel is a consultant for Avanos. JI\u2019s institution received funding by Merck & Co, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15567"}}